Developer docs
API playgroundTry for free, no card

Search company profiles

Bimini Bay LLC

Full company profile

uuid003zjbq

Namestring
Bimini Bay LLC
Legal namestring
Hainan Poly Pharmaceutical Co., Ltd. (海南普利制药股份有限公司)
Company typeenum
Public
Founded yearint
1992
Descriptiontext

Hainan Poly Pharmaceutical Co., Ltd. (海南普利制药股份有限公司) is a vertically integrated Chinese pharmaceutical manufacturer founded in 1992 and publicly listed on the Shenzhen Stock Exchange Growth Enterprise Market (ticker 300630) since 2017. The company operates three manufacturing bases — Haikou (Hainan), Hangzhou (Zhejiang), and Anqing (Anhui) — plus an R&D institute in Beijing, collectively spanning over 500 acres with capabilities in injectables, tablets, capsules, granules, dry suspensions, ointments, eye drops, pre-filled syringes, oral liquids, and APIs. Its technology platform includes membrane separation, high-efficiency purification, micronization, high-activity closed isolation systems, spray and lyophilization drying, with cGMP compliance certified by US FDA, EU EMA, WHO, and China NMPA. Beyond conventional generics, Poly operates a synthetic biology platform (CRISPR/Cas-engineered E. coli, yeast, glutamic acid bacteria) producing health product ingredients and an emerging BNCT (Boron Neutron Capture Therapy) drug pipeline developed jointly with the Chinese Academy of Sciences Institute of High Energy Physics.

The company generates revenue through three primary streams: pharmaceutical product sales (APIs and finished dosage forms), contract development and manufacturing services (CDMO/CMO covering CRO, CMO, and CSO functions), and international exports to over 30 countries including the US, Germany, France, Netherlands, UK, Canada, and Australia. Core commercial assets include the Fubeiding (desloratadine) anti-allergy franchise commanding over 80% domestic market share, Sodium Nitroprusside Injection with approximately 56% combined market share across China, US, and Netherlands, and a broad cardiovascular, anti-infective, contrast agent, and CNS portfolio. Distribution combines direct sales to 15,000+ medical institutions in China via 1,000+ distributors with international export channels through regulatory approvals. Notable CDMO partnerships include Imunon Inc. for the manufacture of IMNN-001 immunotherapy for ovarian cancer.

The customer base spans Chinese hospital networks, international generic pharmaceutical markets in regulated jurisdictions, and global pharmaceutical companies seeking contract manufacturing services. Pricing is driven through China's centralized procurement/tender system for domestic sales and contract-based export arrangements internationally, with publicly disclosed pricing not available. The company holds 100+ international marketing approvals, 21 products with 36 FDA marketing approvals, 97 innovation patents (including 80 invention patents), and 260 total product approvals — supporting a multi-jurisdictional generics, specialty injectable, and emerging CDMO/synthetic biology platform business model.

Short descriptiontext

Hainan Poly Pharmaceutical is a vertically integrated Chinese generic drug manufacturer (Shenzhen GEM: 300630) producing APIs, injectables, and oral solids across three manufacturing bases, exporting to 30+ countries with FDA/EMA/WHO cGMP certifications and operating a growing CDMO/CMO services business.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHaikou, China
HQ citystring
Haikou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, active pharmaceutical ingredients, injectable formulations, contract drug manufacturing, finished dosage forms
Industry3 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from manufacturing and selling pharmaceutical products including APIs, injectables, oral solids, eye drops, and other dosage forms to domestic and international markets.

biminibaysailing.com
2CDMO/CMO Services
TypeProfessional Services
Description

Contract development and manufacturing services for domestic and foreign customers, providing R&D and production support from clinical approval to commercialization.

biminibaysailing.com
3International Export
TypeTransaction Fee
Description

Products exported to US, Germany, France, Netherlands, UK, Canada, Australia and other countries through international regulatory approvals.

biminibaysailing.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1芙必叮 (Fubiding)
Description

Desloratadine product series including tablets, dry suspension, oral solution - flagship anti-allergy brand with over 80% domestic market share

biminibaysailing.com
+5 more records
Core offering1 text field

Hainan Poly Pharmaceutical is a vertically integrated pharmaceutical manufacturer that develops, registers, produces and sells Active Pharmaceutical Ingredients (APIs) and finished dosage forms — injectables, tablets, capsules, dry suspensions, granules, eye drops, ointments, pre-filled syringes and oral liquids — across three production bases in Haikou, Hangzhou and Anqing, with lines certified to US FDA, EU EMA, WHO and China NMPA cGMP standards. It also offers one-stop CDMO/CMO services (CRO + CMO + CSO) covering R&D, regulatory registration, manufacturing and overseas sales for domestic and foreign pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 地氯雷他定片国内市场占有率超80%
+3 more records
Product overview1 text field

Poly Pharm (海南普利制药) is a vertically integrated pharmaceutical company offering a comprehensive portfolio of finished pharmaceutical products, Active Pharmaceutical Ingredients (APIs), and contract manufacturing services. The company operates three manufacturing bases (Hainan, Zhejiang, Anhui) and one R&D institute (Beijing) with capabilities spanning injectables, tablets, capsules, granules, dry suspensions, ointments, eye drops, pre-filled syringes, and oral liquids. Core products include the anti-allergy Fubeiding (芙必叮) series with over 80% domestic market share, cardiovascular drugs like Sodium Nitroprusside Injection, anti-infectives like Azithromycin Injection, and contrast agents like Iopamidol. The company provides CDMO/CMO services from R&D through commercialization, including CRO, CMO, and CSO for global markets. Emerging areas include BNCT boron drugs for cancer treatment and synthetic biology products.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

Deep CDMO cooperation with US innovative pharmaceutical company Imunon for developing new immunotherapy drug IMNN-001 for ovarian cancer treatment. Poly provided high-quality clinical batch samples for early clinical trials with excellent results in Phase II trials showing improved overall survival.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint establishment of Beijing Poly Biopharm innovation drug R&D platform focusing on BNCT (Boron Neutron Capture Therapy) drugs and new targeted boron drugs. Cooperation with core advantages in BNCT technology.

3Zhejiang University
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Strong partnerships established for BNCT new boron carrier development, combining drug design, pharmacology and toxicology research, and CMC expertise.

biminibaysailing.com
4Zhejiang Roly Pharm (瑞利药业)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Wholly-owned subsidiary sales company covering domestic marketing with network over 15,000 medical institutions, 5,000+ secondary and above hospitals, 10,000+ primary healthcare institutions.

biminibaysailing.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Indian-headquartered generic pharma with strong US injectable franchise and FDA-inspected manufacturing. Comparable on generic injectable launches in the US market and complex formulation capabilities.

TypeBroad incumbent
Description

Large Indian generic manufacturer with extensive FDA approvals and vertically integrated API manufacturing across injectables and orals. Closely comparable on regulated-market generic injectables + API integration strategy.

TypeDirect peer
Description

Leading Chinese API manufacturer with significant US FDA and EU EMA approvals for finished formulations, including generic cardiovascular and CNS products overlapping with Poly's portfolio. Closely comparable on international regulated-market generics strategy.

TypeDirect peer
Description

Chinese vertically-integrated API-to-finished-product manufacturer with international (FDA/EMA) approvals and a CDMO business model structurally similar to Poly's. Directly comparable on integrated CDMO/CMO positioning targeting both domestic and US/EU markets.

TypeBroad incumbent
Description

Diversified Chinese pharma conglomerate with API, finished formulation, CDMO, and international expansion across regulated markets. Comparable on the breadth of capabilities (API + formulations + CDMO + overseas approvals), but with a much larger portfolio and biosimilar exposure.

TypeBroad incumbent
Description

India-headquartered global generic and CDMO player with deep US FDA inspection track record and integrated API-to-formulations model. Comparable on vertically-integrated generics + CDMO + complex injectables (including oncology) targeting regulated markets.

TypeBroad incumbent
Description

Large Hong Kong-listed Chinese pharma with significant API and finished-product manufacturing, including injectables, and a sizable CDMO operation. Comparable on integrated pharma manufacturing with international ambitions, though substantially larger and more diversified than Poly.

8Zhejiang Hisun Pharmaceutical
TypeDirect peer
Description

Chinese API and finished formulation manufacturer with FDA/EMA approvals and growing international CDMO business. Comparable on integrated API + finished product + overseas regulated markets strategy.

9Shanghai Pharmaceuticals Holding
TypeBroad incumbent
Description

State-owned Chinese pharmaceutical manufacturer and distributor with API and finished formulation businesses plus domestic hospital distribution. Comparable on domestic hospital channel and integrated manufacturing, though more distribution-heavy than Poly.

10Jiangsu Hengrui Medicine
TypeBroad incumbent
Description

China's largest innovative pharma with growing international injectable and biosimilar business targeting FDA approvals. Comparable on Chinese-pharma-with-regulated-market-ambitions positioning, though primarily innovation-led rather than CDMO/generic.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bimini Bay LLC

Generic Pharmaceuticalsbiminibaysailing.com

Hainan Poly Pharmaceutical is a vertically integrated Chinese generic drug manufacturer (Shenzhen GEM: 300630) producing APIs, injectables, and oral solids across three manufacturing bases, exporting to 30+ countries with FDA/EMA/WHO cGMP certifications and operating a growing CDMO/CMO services business.

What Bimini Bay LLC does

Hainan Poly Pharmaceutical Co., Ltd. (海南普利制药股份有限公司) is a vertically integrated Chinese pharmaceutical manufacturer founded in 1992 and publicly listed on the Shenzhen Stock Exchange Growth Enterprise Market (ticker 300630) since 2017. The company operates three manufacturing bases — Haikou (Hainan), Hangzhou (Zhejiang), and Anqing (Anhui) — plus an R&D institute in Beijing, collectively spanning over 500 acres with capabilities in injectables, tablets, capsules, granules, dry suspensions, ointments, eye drops, pre-filled syringes, oral liquids, and APIs. Its technology platform includes membrane separation, high-efficiency purification, micronization, high-activity closed isolation systems, spray and lyophilization drying, with cGMP compliance certified by US FDA, EU EMA, WHO, and China NMPA. Beyond conventional generics, Poly operates a synthetic biology platform (CRISPR/Cas-engineered E. coli, yeast, glutamic acid bacteria) producing health product ingredients and an emerging BNCT (Boron Neutron Capture Therapy) drug pipeline developed jointly with the Chinese Academy of Sciences Institute of High Energy Physics.

The company generates revenue through three primary streams: pharmaceutical product sales (APIs and finished dosage forms), contract development and manufacturing services (CDMO/CMO covering CRO, CMO, and CSO functions), and international exports to over 30 countries including the US, Germany, France, Netherlands, UK, Canada, and Australia. Core commercial assets include the Fubeiding (desloratadine) anti-allergy franchise commanding over 80% domestic market share, Sodium Nitroprusside Injection with approximately 56% combined market share across China, US, and Netherlands, and a broad cardiovascular, anti-infective, contrast agent, and CNS portfolio. Distribution combines direct sales to 15,000+ medical institutions in China via 1,000+ distributors with international export channels through regulatory approvals. Notable CDMO partnerships include Imunon Inc. for the manufacture of IMNN-001 immunotherapy for ovarian cancer.

The customer base spans Chinese hospital networks, international generic pharmaceutical markets in regulated jurisdictions, and global pharmaceutical companies seeking contract manufacturing services. Pricing is driven through China's centralized procurement/tender system for domestic sales and contract-based export arrangements internationally, with publicly disclosed pricing not available. The company holds 100+ international marketing approvals, 21 products with 36 FDA marketing approvals, 97 innovation patents (including 80 invention patents), and 260 total product approvals — supporting a multi-jurisdictional generics, specialty injectable, and emerging CDMO/synthetic biology platform business model.

Bimini Bay LLC firmographics

Firmographics
Name
Bimini Bay LLC
Legal name
Hainan Poly Pharmaceutical Co., Ltd. (海南普利制药股份有限公司)
Website
https://biminibaysailing.com
Company type
Public
Founded year
1992
Operating status
Operating
Headcount range
1–10 employees
Short description
Hainan Poly Pharmaceutical is a vertically integrated Chinese generic drug manufacturer (Shenzhen GEM: 300630) producing APIs, injectables, and oral solids across three manufacturing bases, exporting to 30+ countries with FDA/EMA/WHO cGMP certifications and operating a growing CDMO/CMO services business.
Ownership category
akta.pro rank

Bimini Bay LLC industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • Generic pharmaceuticals
  • Active pharmaceutical ingredients
  • Injectable formulations
  • Contract drug manufacturing
  • Finished dosage forms

Where Bimini Bay LLC is headquartered

Location

Headquarters

HQ city
Haikou
HQ country
China
HQ region
Asia

Offices4 records

Markets served

Bimini Bay LLC business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Revenue from manufacturing and selling pharmaceutical products including APIs, injectables, oral solids, eye drops, and other dosage forms to domestic and international markets.
  2. CDMO/CMO Services: Contract development and manufacturing services for domestic and foreign customers, providing R&D and production support from clinical approval to commercialization.
  3. International Export: Products exported to US, Germany, France, Netherlands, UK, Canada, Australia and other countries through international regulatory approvals.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Bimini Bay LLC product offering

Product offering

Core offering

Hainan Poly Pharmaceutical is a vertically integrated pharmaceutical manufacturer that develops, registers, produces and sells Active Pharmaceutical Ingredients (APIs) and finished dosage forms — injectables, tablets, capsules, dry suspensions, granules, eye drops, ointments, pre-filled syringes and oral liquids — across three production bases in Haikou, Hangzhou and Anqing, with lines certified to US FDA, EU EMA, WHO and China NMPA cGMP standards. It also offers one-stop CDMO/CMO services (CRO + CMO + CSO) covering R&D, regulatory registration, manufacturing and overseas sales for domestic and foreign pharmaceutical partners.

Product overview

Poly Pharm (海南普利制药) is a vertically integrated pharmaceutical company offering a comprehensive portfolio of finished pharmaceutical products, Active Pharmaceutical Ingredients (APIs), and contract manufacturing services. The company operates three manufacturing bases (Hainan, Zhejiang, Anhui) and one R&D institute (Beijing) with capabilities spanning injectables, tablets, capsules, granules, dry suspensions, ointments, eye drops, pre-filled syringes, and oral liquids. Core products include the anti-allergy Fubeiding (芙必叮) series with over 80% domestic market share, cardiovascular drugs like Sodium Nitroprusside Injection, anti-infectives like Azithromycin Injection, and contrast agents like Iopamidol. The company provides CDMO/CMO services from R&D through commercialization, including CRO, CMO, and CSO for global markets. Emerging areas include BNCT boron drugs for cancer treatment and synthetic biology products.

Differentiator

Problem solved

Functional benefit

Brands

  • 芙必叮 (Fubiding): Desloratadine product series including tablets, dry suspension, oral solution - flagship anti-allergy brand with over 80% domestic market share
  • 诺福丁 (Nuofu Ding)
  • 普利舒奥
  • 闪释 (Shan Shi)
  • 普利泮妥
  • 普利舒利

Quantifiable outcome

  • 地氯雷他定片国内市场占有率超80%
  • +3 more outcomes

Companies that use Bimini Bay LLC

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Bimini Bay LLC technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Bimini Bay LLC partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Imunon, Inc.coreStrategic or Co-development Partner · 1 November 2024Deep CDMO cooperation with US innovative pharmaceutical company Imunon for developing new immunotherapy drug IMNN-001 for ovarian cancer treatment. Poly provided high-quality clinical batch samples for early clinical trials with excellent results in Phase II trials showing improved overall survival.
  • Chinese Academy of Sciences Institute of High Energy Physics (IHEP)coreStrategic or Co-development PartnerJoint establishment of Beijing Poly Biopharm innovation drug R&D platform focusing on BNCT (Boron Neutron Capture Therapy) drugs and new targeted boron drugs. Cooperation with core advantages in BNCT technology.
  • Zhejiang UniversitymajorStrategic or Co-development PartnerStrong partnerships established for BNCT new boron carrier development, combining drug design, pharmacology and toxicology research, and CMC expertise.
  • Zhejiang Roly Pharm (瑞利药业)coreChannel Partner/ Reseller/ DistributorWholly-owned subsidiary sales company covering domestic marketing with network over 15,000 medical institutions, 5,000+ secondary and above hospitals, 10,000+ primary healthcare institutions.

Scale indicators10 records

Recent moves10 records

Expansion highlights7 records

Bimini Bay LLC competitors and assessment

Company assessment

Broad incumbents

  • Lupin Limited: Indian-headquartered generic pharma with strong US injectable franchise and FDA-inspected manufacturing. Comparable on generic injectable launches in the US market and complex formulation capabilities.
  • Aurobindo Pharma: Large Indian generic manufacturer with extensive FDA approvals and vertically integrated API manufacturing across injectables and orals. Closely comparable on regulated-market generic injectables + API integration strategy.
  • Shanghai Fosun Pharmaceutical: Diversified Chinese pharma conglomerate with API, finished formulation, CDMO, and international expansion across regulated markets. Comparable on the breadth of capabilities (API + formulations + CDMO + overseas approvals), but with a much larger portfolio and biosimilar exposure.
  • Dr. Reddy's Laboratories: India-headquartered global generic and CDMO player with deep US FDA inspection track record and integrated API-to-formulations model. Comparable on vertically-integrated generics + CDMO + complex injectables (including oncology) targeting regulated markets.
  • CSPC Pharmaceutical Group: Large Hong Kong-listed Chinese pharma with significant API and finished-product manufacturing, including injectables, and a sizable CDMO operation. Comparable on integrated pharma manufacturing with international ambitions, though substantially larger and more diversified than Poly.
  • Shanghai Pharmaceuticals Holding: State-owned Chinese pharmaceutical manufacturer and distributor with API and finished formulation businesses plus domestic hospital distribution. Comparable on domestic hospital channel and integrated manufacturing, though more distribution-heavy than Poly.
  • Jiangsu Hengrui Medicine: China's largest innovative pharma with growing international injectable and biosimilar business targeting FDA approvals. Comparable on Chinese-pharma-with-regulated-market-ambitions positioning, though primarily innovation-led rather than CDMO/generic.

Direct peers

  • Zhejiang Huahai Pharmaceutical: Leading Chinese API manufacturer with significant US FDA and EU EMA approvals for finished formulations, including generic cardiovascular and CNS products overlapping with Poly's portfolio. Closely comparable on international regulated-market generics strategy.
  • Apeloa Pharmaceutical: Chinese vertically-integrated API-to-finished-product manufacturer with international (FDA/EMA) approvals and a CDMO business model structurally similar to Poly's. Directly comparable on integrated CDMO/CMO positioning targeting both domestic and US/EU markets.
  • Zhejiang Hisun Pharmaceutical: Chinese API and finished formulation manufacturer with FDA/EMA approvals and growing international CDMO business. Comparable on integrated API + finished product + overseas regulated markets strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Bimini Bay LLC social profiles

Digital presence

Bimini Bay LLC compliance and trust

Trust signal

Compliance9 records

Bimini Bay LLC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bimini Bay LLC leadership team

Management profile

Number of profiles

Bimini Bay LLC subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Bimini Bay LLC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bimini Bay LLC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bimini Bay LLC

What does Bimini Bay LLC do?

Hainan Poly Pharmaceutical is a vertically integrated pharmaceutical manufacturer that develops, registers, produces and sells Active Pharmaceutical Ingredients (APIs) and finished dosage forms — injectables, tablets, capsules, dry suspensions, granules, eye drops, ointments, pre-filled syringes and oral liquids — across three production bases in Haikou, Hangzhou and Anqing, with lines certified to US FDA, EU EMA, WHO and China NMPA cGMP standards. It also offers one-stop CDMO/CMO services (CRO + CMO + CSO) covering R&D, regulatory registration, manufacturing and overseas sales for domestic and foreign pharmaceutical partners.

Is Bimini Bay LLC a public or private company?

Bimini Bay LLC is a public company. It is classified as public and is currently operating.

When was Bimini Bay LLC founded?

Bimini Bay LLC was founded in 1992. It employs 1 to 10 people.

Where is Bimini Bay LLC based?

Bimini Bay LLC is headquartered in Haikou, China, in the Asia region.

How does Bimini Bay LLC make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are CDMO/CMO Services and international Export.

Who are Bimini Bay LLC's main competitors?

Broad incumbents on record are Lupin Limited, Aurobindo Pharma, Shanghai Fosun Pharmaceutical, Dr. Reddy's Laboratories, CSPC Pharmaceutical Group, Shanghai Pharmaceuticals Holding and Jiangsu Hengrui Medicine. Direct peers are Zhejiang Huahai Pharmaceutical, Apeloa Pharmaceutical and Zhejiang Hisun Pharmaceutical.

Does Bimini Bay LLC have an API?

No public API is recorded for Bimini Bay LLC.

What industry is Bimini Bay LLC in?

Bimini Bay LLC's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales